The group is recognizing Dr. Wakelee for her sustained commitment to developing women’s careers in cancer medicine and advancing women investigators in ECOG-ACRIN
EA2212 is a randomized phase 2 study assessing if chemotherapy plus immunotherapy is superior to immunotherapy alone for patients with operable MSI-H/dMMR gastric and/or gastroesophageal junction cancer